Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-07-24
DOI
10.1111/dom.13477
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
- (2018) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- Risk of Amputations Associated with SGLT2 Inhibitors Compared to DPP-4 Inhibitors: A Propensity-Matched Cohort Study
- (2018) Sruthi Adimadhyam et al. DIABETES OBESITY & METABOLISM
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review
- (2018) Karin Rådholm et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database
- (2017) Konstantinos A. Toulis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
- (2017) Jacob A. Udell et al. CIRCULATION
- Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
- (2016) Angelo Avogaro et al. Cardiovascular Diabetology
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Real-World Evidence — What Is It and What Can It Tell Us?
- (2016) Rachel E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case Definitions for Acute Myocardial Infarction in Administrative Databases and Their Impact on In-Hospital Mortality Rates
- (2012) Amy Metcalfe et al. HEALTH SERVICES RESEARCH
- A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent
- (2012) Bruce Fireman et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now